Bertis to Participate in Korea's Largest Proteomics Conference, KHUPO 2024

- Poster presentation on research outcomes in biomarker candidates for prostate cancer diagnosis, and an educational lecture on QC and interpretation of mass spectrometry-based proteomics data

- Setup of a promotional booth from June 25 to 27 to introduce the mass spectrometry-based omics analysis solution PASS, and its customized peptide synthesis solution, PEPS PRO.

On June 25th, Bertis, a company specializing in the development of proteomics-based precision medicine technology (led by CEOs Dong-young Noh and Seung-man Han), announced that it will participate in 'KHUPO 2024 YEOSU (KHUPO 2024)', the largest domestic proteomics conference hosted by The Korean Human Proteome Organization (KHUPO).

<Image: Logos of KHUPO and Bertis>

KHUPO 2024, to be held from June 25 to 27 at the Yeosu Expo Convention Center, is expected to be a platform for sharing new research achievements and innovative technologies in the field of proteomics under the theme "PROUD: PROteomics Unlimited Desire." As a leading domestic company in the proteomics field, Bertis will present research achievements, conduct educational sessions, and operate a promotional booth during KHUPO 2024.

Dr. Jin-Young Cho from the Biomarker Research Team at Bertis R&D division will present a poster on "Novel Diagnostic Biomarkers for Prostate Cancer Discovered Using a Mass Spectrometry-Based Pipeline" on Wednesday, the 26th at 11:45 AM, and Thursday, the 27th at 11:30 AM.

<Image: Discovery process of PCa biomarker candidates>

Prostate Cancer(PCa) can often be detected by testing the levels of Prostate-Specific Antigen (PSA) in blood. However, the level of PSA is also rise in cases of benign prostatic hyperplasia and prostatitis, necessitating a more accurate diagnostic test specifically for PCa. In this study, the Bertis team used liquid chromatography data-independent acquisition tandem-mass spectrometry (LC-DIA-MS/MS) to analyze the human serum of 50 healthy controls (HCs), 42 individuals with benign conditions, and 90 patients with PCa. The aim was to discover potential biomarkers for PCa diagnosis. They identified 24 differentially expressed proteins (DEPs) in PCa patients compared to healthy controls and those with benign conditions. In addition, bioinformatic analysis on public data of prostate cancer-associated biomarkers and prognosis before and after treatment, a list of 50 proteins was created. Takes together, a total of 74 serum proteins were selected as potential prostate cancer biomarker candidates.

In the education session, Dr. Sunghyun Huh, Head of the Bioinformatics Team at Bertis R&D division will deliver a lecture titled “Interpretation of Mass Spectrometry-Based Proteomics Data for Biological Research”. The session will introduce the analysis, processing, and interpretation of mass spectrometry-based proteomics data, covering relevant research examples. The lecture is scheduled for Wednesday, the 26th, at 9:00 AM in the 1st floor lecture hall, as the first session of ‘Education Session 3: Proteomics meets AI’

During the event, Bertis will operate a promotional booth to showcase its mass spectrometry-based omics analysis solution, PASS (Pan-omics Analysis Service & Solution), alongside its customized peptide synthesis service, PEPS PRO. PEPS PRO provides synthesis services for customized peptides, PNAs, and various organic compounds utilizing the company’s GMP facilities and highly skilled professionals, ensuring high-quality products at competitive prices. The company plans to utilize the KHUPO 2024 platform to initiate a marketing campaign to promote PEPS PRO.

Seung-man Han, CEO of Bertis, stated, "Bertis is advancing and commercializing proteomics technologies to contribute to the development of practical solutions in clinical settings for domestic biotech companies." He further emphasized, "We are dedicated to sharing innovative technologies and research outcomes to broaden the impact of proteomics in Korea and bolster technological competitiveness."